Press Releases

May 6, 2024

Thubrikar Aortic Valve Announces Clinical Success of the New Precision 2™ Delivery Catheter

December 15, 2023

Thubrikar Aortic Valve Announces Authorization to Expand the TAVI-1 CE Mark Trial with the Precision 2™ Delivery Catheter

May 2, 2023

Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study with Novel Optimum TAV™ at EuroPCR 2023

October 21, 2022

Thubrikar Aortic Valve Completes Initial CE Mark-Enabling TAVI-1 Study

August 2, 2022

Thubrikar Aortic Valve Announces Initial 30-Day Outcomes of CE Mark-Enabling TAVI-1 Study

December 17, 2021

Thubrikar Aortic Valve Announces Authorization to Initiate Patient Implants Toward CE Mark Approval of Optimum TAV, and Development of Its Novel Precision 2 Delivery Catheter

January 8, 2019

Thubrikar Announces First-in-Human Implant with the Optimum TAVI System

July 16, 2018

Thubrikar and Labcor Strengthen Partnership with Nearly $1 Million Investment in Thubrikar

In the Media

May 5, 2020

CM Medical

6 of the Best in Structural Heart

March 18, 2019

CEOCFO Magazine

With their transcatheter aortic valve now ready to enter clinical trials, Thubrikar Aortic Valve is offering hope to patients with aortic valve disease for significantly reduced trauma, complications and recovery

July 8, 2014

Med Device Online

Reverse Engineering a Human Heart Valve

May 9, 2014

Philadelphia Business Journal

Medical device firm targets a heart valve market in flux